Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) Anticorps:
anti-Dog (Canine) Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Loss of SMN2 (Montrer SMN1 Anticorps) is associated with spinal muscular atrophy.
While the above conclusions are firmly supported by the experimental data presented, we discuss and justify the need of deep proteomic techniques for the study of SMN (Montrer STMN1 Anticorps) complex components (orphan and bound) turn-over to understand the physiological relevant mechanisms of degradation of SMN (Montrer STMN1 Anticorps) and SMNDelta7 (SMN1 (Montrer SMN1 Anticorps) and SMN2 (Montrer SMN1 Anticorps))in the cell
Results report exon 6B, a novel exon, generated by exonization of an intronic Alu-like sequence from both SMN1 (Montrer SMN1 Anticorps) and SMN2 (Montrer SMN1 Anticorps), and validate the expression of exon 6B-containing transcripts SMN6B and SMN6BDelta7 in human tissues and cell lines. hnRNP C is shown to be a potential regulator of its expression and demonstrate that SMN6B is a substrate of nonsense-mediated decay. Also, an interaction of SMN6B with Gemin2 (Montrer GEMIN2 Anticorps) was found.
Our work has not only expanded the number of pre-mRNA targets for RBM10 (Montrer RBM10 Anticorps), but identified RBM10 (Montrer RBM10 Anticorps) as a novel regulator of SMN2 (Montrer SMN1 Anticorps) alternative inclusion.
We have now identified A-44G as an additional positive disease modifier, present in a group of patients carrying 3 SMN2 (Montrer SMN1 Anticorps) copies. Through systematic mutagenesis, we found that the improvement in exon 7 splicing is mainly attributable to the A-44G transition in intron 6.
Ongoing research may yield other treatments, especially for children who have not responded to Spinraza. A gene therapy delivered by adeno (Montrer ADORA2A Anticorps)-associated virus type 9 (AAV9) is designed to replace or correct SMN1 (Montrer SMN1 Anticorps) . Cure SMA (Montrer SMN1 Anticorps) is supporting research in this area as well as studies of small molecules that correct SMN2 (Montrer SMN1 Anticorps) splicing or spur it to produce more protein.
To determine the dependence of oligodendrocyte (OL)on the Smn (Montrer STMN1 Anticorps) protein(SMN1 (Montrer SMN1 Anticorps)), we utilized the Smn (Montrer STMN1 Anticorps)-/-;SMN2 (Montrer SMN1 Anticorps) (severe) mouse model. Our data suggest that despite the multi-functionality and ubiquitous expression of the Smn (Montrer STMN1 Anticorps) protein, it does not play a key role in myelination of the CNS, at least in the context of spinal muscular atrophy pathogenesis.
The spleen is disproportionately small in the murine model of spinal muscular atrophy with a deficiency in SMN2 (Montrer SMN1 Anticorps).
Low SMN2 (Montrer SMN1 Anticorps) expression is associated with Spinal Muscular Atrophy.
we have characterized SMN (Montrer STMN1 Anticorps)-C1, a low-molecular weight compound that corrects alternative splicing defects of SMN2 (Montrer SMN1 Anticorps) exon 7. We evaluated SMN (Montrer STMN1 Anticorps)-C1 pharmacokinetics in mice, the dose-response of SMN (Montrer STMN1 Anticorps)-C1 induction of SMN (Montrer STMN1 Anticorps) protein in two mouse models of SMA (Montrer SMN1 Anticorps), the correlation between SMN (Montrer STMN1 Anticorps)-C1 PK and SMN (Montrer STMN1 Anticorps) protein induction in vivo, and demonstrated that the peripheral SMN (Montrer STMN1 Anticorps) protein levels correlated with CNS SMN (Montrer STMN1 Anticorps) protein levels
This gene is part of a 500 kb inverted duplication on chromosome 5q13. This duplicated region contains at least four genes and repetitive elements which make it prone to rearrangements and deletions. The repetitiveness and complexity of the sequence have also caused difficulty in determining the organization of this genomic region. The telomeric and centromeric copies of this gene are nearly identical and encode the same protein. While mutations in the telomeric copy are associated with spinal muscular atrophy, mutations in this gene, the centromeric copy, do not lead to disease. This gene may be a modifier of disease caused by mutation in the telomeric copy. The critical sequence difference between the two genes is a single nucleotide in exon 7, which is thought to be an exon splice enhancer. Note that the nine exons of both the telomeric and centromeric copies are designated historically as exon 1, 2a, 2b, and 3-8. It is thought that gene conversion events may involve the two genes, leading to varying copy numbers of each gene. The full length protein encoded by this gene localizes to both the cytoplasm and the nucleus. Within the nucleus, the protein localizes to subnuclear bodies called gems which are found near coiled bodies containing high concentrations of small ribonucleoproteins (snRNPs). This protein forms heteromeric complexes with proteins such as SIP1 and GEMIN4, and also interacts with several proteins known to be involved in the biogenesis of snRNPs, such as hnRNP U protein and the small nucleolar RNA binding protein. Four transcript variants encoding distinct isoforms have been described.
component of gems 1
, survival motor neuron protein
, tudor domain containing 16B
, survival of motor neuron 2, centromeric